Cara Therapeutics Inc (CARA) : Rho Capital Partners Inc scooped up 400,000 additional shares in Cara Therapeutics Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 9, 2016. The investment management firm now holds a total of 3,068,057 shares of Cara Therapeutics Inc which is valued at $16,015,258.Cara Therapeutics Inc makes up approximately 8.29% of Rho Capital Partners Inc’s portfolio.
Other Hedge Funds, Including , Nine Chapters Capital Management sold out all of its stake in CARA during the most recent quarter. The investment firm sold 40,500 shares of CARA which is valued $211,410.Proshare Advisors reduced its stake in CARA by selling 2,354 shares or 9.5% in the most recent quarter. The Hedge Fund company now holds 22,436 shares of CARA which is valued at $124,744.Jennison Associates boosted its stake in CARA in the latest quarter, The investment management firm added 4,224 additional shares and now holds a total of 660,691 shares of Cara Therapeutics Inc which is valued at $3,673,442. Quantbot Technologies Lp added CARA to its portfolio by purchasing 3,481 company shares during the most recent quarter which is valued at $21,234.
Cara Therapeutics Inc opened for trading at $5.22 and hit $5.37 on the upside on Friday, eventually ending the session at $5.22, with a gain of 0.19% or 0.01 points. The heightened volatility saw the trading volume jump to 3,24,080 shares. Company has a market cap of $142 M.
On the company’s financial health, Cara Therapeutics Inc reported $-0.39 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on May 5, 2016. Analyst had a consensus of $-0.40. The company had revenue of $.01 million for the quarter, compared to analysts expectations of $.03 million. The company’s revenue was down -98.6 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.21 EPS.
Many Wall Street Analysts have commented on Cara Therapeutics Inc. Shares were Reiterated by Laidlaw on Feb 29, 2016 to “Buy” and Lowered the Price Target to $ 17 from a previous price target of $30 .
Cara Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. The Company is engaged in developing product candidates that focus on the body’s peripheral nervous system. Its product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845 for acute and chronic pain and CR701 for neuropathic and inflammatory pain. CR845 is a peripherally-acting kappa opioid receptor agonist for the treatment of both acute and chronic pain. I.V. CR845 is an injectable version of its peripheral kappa opioid receptor agonist which is designed to provide pain relief without stimulating mu opioid receptors. CR701 is a peripherally-restricted mixed-CB1/CB2 receptor agonist that interacts with these cannabinoid receptor subtypes with no off-target activities.